SCHEDULE: EARNEST Partners Reduces ORASURE Stake Below 5%

EARNEST Partners LLC has filed an amended Schedule 13G, reporting that its beneficial ownership in ORASURE Technologies Inc. common stock fell below 5% as of December 31, 2022.

Summary

• EARNEST Partners LLC, an investment adviser, filed an Amendment No. 1 to Schedule 13G regarding its holdings in ORASURE TECHNOLOGIES INC.
• The filing indicates that EARNEST Partners LLC ceased to beneficially own more than 5% of ORASURE TECHNOLOGIES INC's common stock as of December 31, 2022.
• As of the filing, EARNEST Partners LLC beneficially owns 795 shares, representing 0.0% of the class of securities.
• The reporting person stated that they never held shares of the issuer with a control intent.
• The filing itself was submitted late due to an inadvertent oversight by EARNEST Partners LLC.

Sentiment

Score: 4

Explanation: The filing is largely neutral for ORASURE TECHNOLOGIES INC, as it reports a passive reduction in stake by an institutional investor. The late filing is a negative for the reporting entity, not the issuer. A reduction in institutional ownership can be seen as a slight negative signal, but without context on the reason for the sale, it is not strongly negative.

Negatives

• A significant institutional investor, EARNEST Partners LLC, reduced its beneficial ownership in ORASURE TECHNOLOGIES INC below the 5% reporting threshold.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding ORASURE TECHNOLOGIES INC's future performance or operations.

Industry Context

This filing reflects a routine change in institutional ownership and does not provide specific insights into broader industry trends for the biotechnology or medical device sectors in which ORASURE TECHNOLOGIES INC operates. It primarily concerns the portfolio management decisions of EARNEST Partners LLC.

Stakeholder Impact

• Shareholders of ORASURE TECHNOLOGIES INC may view the reduction in institutional ownership as a potential signal of decreased confidence, which could influence investment decisions.

Key Dates

Recommendation

The filing indicates a passive reduction in ownership by an institutional investor, EARNEST Partners LLC, below the 5% threshold. While a reduction in institutional holdings can sometimes signal a lack of confidence, this filing does not provide specific reasons for the sale or any new negative information about ORASURE TECHNOLOGIES INC's operations or financial health. Therefore, without additional context or company-specific news, a 'hold' recommendation is appropriate for existing investors, as the information is not strong enough to warrant a 'buy' or 'sell' decision based solely on this filing.

Keywords

ORASURE TECHNOLOGIES INC, EARNEST Partners LLC, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Stake Reduction